SG11202000441QA - Process for the preparation of n-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide - Google Patents
Process for the preparation of n-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamideInfo
- Publication number
- SG11202000441QA SG11202000441QA SG11202000441QA SG11202000441QA SG11202000441QA SG 11202000441Q A SG11202000441Q A SG 11202000441QA SG 11202000441Q A SG11202000441Q A SG 11202000441QA SG 11202000441Q A SG11202000441Q A SG 11202000441QA SG 11202000441Q A SG11202000441Q A SG 11202000441QA
- Authority
- SG
- Singapore
- Prior art keywords
- squibb
- bristol
- drive
- new jersey
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/22—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762534908P | 2017-07-20 | 2017-07-20 | |
| PCT/US2018/042797 WO2019018592A2 (en) | 2017-07-20 | 2018-07-19 | PROCESS FOR THE PREPARATION OF N- ((1R, 2S, 5R) -5- (TERT-BUTYLAMINO) -2 - ((S) -3- (7-TERT-BUTYLPYRAZOLO [1,5-A]] 1,3 , 5] triazin-4-ylamino) -2-oxopyrrolidin-1-yl) cyclohexyl) acetamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000441QA true SG11202000441QA (en) | 2020-02-27 |
Family
ID=63834628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000441QA SG11202000441QA (en) | 2017-07-20 | 2018-07-19 | Process for the preparation of n-((1r,2s,5r)-5-(tert-butylamino)-2-((s)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11254679B2 (ja) |
| EP (1) | EP3655395B1 (ja) |
| JP (1) | JP2020527576A (ja) |
| KR (1) | KR20200031656A (ja) |
| CN (1) | CN110933946A (ja) |
| AU (1) | AU2018304290B2 (ja) |
| BR (1) | BR112020000418A2 (ja) |
| CA (1) | CA3070423A1 (ja) |
| CY (1) | CY1125023T1 (ja) |
| DK (1) | DK3655395T3 (ja) |
| EA (1) | EA202090346A1 (ja) |
| ES (1) | ES2907640T3 (ja) |
| HR (1) | HRP20220264T8 (ja) |
| HU (1) | HUE058049T2 (ja) |
| IL (2) | IL293088A (ja) |
| LT (1) | LT3655395T (ja) |
| PL (1) | PL3655395T3 (ja) |
| PT (1) | PT3655395T (ja) |
| RS (1) | RS62941B1 (ja) |
| SG (1) | SG11202000441QA (ja) |
| SI (1) | SI3655395T1 (ja) |
| WO (1) | WO2019018592A2 (ja) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020014574A2 (pt) * | 2018-01-22 | 2020-12-08 | Bristol-Myers Squibb Company | Composições e métodos para o tratamento do câncer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4546923B2 (ja) * | 2003-05-30 | 2010-09-22 | チョンウェ ファーマ コーポレーション | ベータストランドミメティックスおよびこれに関連した方法 |
| US7671062B2 (en) * | 2006-07-28 | 2010-03-02 | Bristol-Myers Squibb Company | Modulators of chemokine receptor activity, crystalline forms and process |
| US7629351B2 (en) * | 2006-07-28 | 2009-12-08 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process |
| CN100593536C (zh) * | 2007-01-09 | 2010-03-10 | 吉尔生化（上海）有限公司 | 一种n-芴甲氧羰基-n-三苯甲基-d-谷氨酰胺的合成法 |
| US8383812B2 (en) * | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| WO2013100132A1 (ja) * | 2011-12-28 | 2013-07-04 | 中外製薬株式会社 | ペプチド化合物の環化方法 |
-
2018
- 2018-07-19 EA EA202090346A patent/EA202090346A1/ru unknown
- 2018-07-19 CN CN201880046394.0A patent/CN110933946A/zh active Pending
- 2018-07-19 IL IL293088A patent/IL293088A/en unknown
- 2018-07-19 LT LTEPPCT/US2018/042797T patent/LT3655395T/lt unknown
- 2018-07-19 PL PL18785785T patent/PL3655395T3/pl unknown
- 2018-07-19 ES ES18785785T patent/ES2907640T3/es active Active
- 2018-07-19 JP JP2020502357A patent/JP2020527576A/ja active Pending
- 2018-07-19 EP EP18785785.9A patent/EP3655395B1/en active Active
- 2018-07-19 SI SI201830566T patent/SI3655395T1/sl unknown
- 2018-07-19 AU AU2018304290A patent/AU2018304290B2/en not_active Ceased
- 2018-07-19 CA CA3070423A patent/CA3070423A1/en active Pending
- 2018-07-19 BR BR112020000418-9A patent/BR112020000418A2/pt active Search and Examination
- 2018-07-19 HU HUE18785785A patent/HUE058049T2/hu unknown
- 2018-07-19 KR KR1020207004510A patent/KR20200031656A/ko active IP Right Grant
- 2018-07-19 RS RS20220175A patent/RS62941B1/sr unknown
- 2018-07-19 DK DK18785785.9T patent/DK3655395T3/da active
- 2018-07-19 WO PCT/US2018/042797 patent/WO2019018592A2/en unknown
- 2018-07-19 PT PT187857859T patent/PT3655395T/pt unknown
- 2018-07-19 US US16/631,915 patent/US11254679B2/en active Active
- 2018-07-19 SG SG11202000441QA patent/SG11202000441QA/en unknown
- 2018-07-19 HR HRP20220264TT patent/HRP20220264T8/hr unknown
-
2020
- 2020-01-14 IL IL272034A patent/IL272034B/en unknown
-
2022
- 2022-02-22 US US17/677,312 patent/US20220177482A1/en not_active Abandoned
- 2022-02-23 CY CY20221100161T patent/CY1125023T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019018592A2 (en) | 2019-01-24 |
| LT3655395T (lt) | 2022-03-10 |
| EP3655395A2 (en) | 2020-05-27 |
| AU2018304290B2 (en) | 2022-11-17 |
| BR112020000418A2 (pt) | 2020-07-14 |
| DK3655395T3 (da) | 2022-03-07 |
| US20200223852A1 (en) | 2020-07-16 |
| IL272034A (en) | 2020-03-31 |
| US20220177482A1 (en) | 2022-06-09 |
| PT3655395T (pt) | 2022-02-22 |
| HRP20220264T1 (hr) | 2022-05-13 |
| PL3655395T3 (pl) | 2022-03-07 |
| US11254679B2 (en) | 2022-02-22 |
| ES2907640T3 (es) | 2022-04-25 |
| WO2019018592A3 (en) | 2019-02-28 |
| JP2020527576A (ja) | 2020-09-10 |
| AU2018304290A8 (en) | 2020-04-02 |
| KR20200031656A (ko) | 2020-03-24 |
| SI3655395T1 (sl) | 2022-04-29 |
| HUE058049T2 (hu) | 2022-06-28 |
| EA202090346A1 (ru) | 2020-08-18 |
| IL293088A (en) | 2022-07-01 |
| AU2018304290A1 (en) | 2020-03-05 |
| CN110933946A (zh) | 2020-03-27 |
| IL272034B (en) | 2022-06-01 |
| HRP20220264T8 (hr) | 2022-05-27 |
| EP3655395B1 (en) | 2021-12-01 |
| CA3070423A1 (en) | 2019-01-24 |
| RS62941B1 (sr) | 2022-03-31 |
| CY1125023T1 (el) | 2023-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808678QA (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions | |
| SG11201811490XA (en) | Cd3 binding antibodies | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201906883SA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201807426WA (en) | Immunomodulators | |
| CA2859619C (en) | Bromodomain inhibitors | |
| SG11201808163WA (en) | 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201407923TA (en) | Liquid optical adhesive compositions | |
| SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201810454YA (en) | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201901203PA (en) | Treatment and sustained virologic remission of hiv infection by antibodies to cd4 in haart stabilized patients | |
| SG11201804205UA (en) | Media mixing chamber | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201901409YA (en) | Polymerizing composition, method of manufacture thereof and articles comprising the same | |
| SG11201407337QA (en) | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors |